Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (3014)	10/4/2017 2:22:04 PM
From: DewDiligence_on_SI	Read Replies (1) of 3027

I'm pretty sure the only issue is whether the FDA approves a 40mg generic from one of the first-filer applicants (including NVS/MNTA) within six months of yesterday; if they do, all approved 40mg products from first-filers will share the (remaining amount of) 180-day H-W exclusivity. If the above is true, 180-day H-W exclusivity will end up constraining nobody—unless FDA approves a 40mg generic in the next six months from a non-first-filer applicant, which is highly unlikely, IMO. Yes, TEVA could (and probably would) launch a 40mg AG if there are multiple approved generics.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next